Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026.

• Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1.
• Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix.
• Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology.
• Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ramp-up with approvals in 33 International markets, alongside continued investment in science-based innovation and medical education.
• Core EBITDA2 margin expansion of 328 basis points at constant currency, ahead of initial expectations for the first half, with Core EBITDA reaching 802 million USD, up 42.8% year-on-year at constant currency, and a Core EBITDA margin of 25.6%.
• Core EPS3 grew to 2.34 USD, up 68.5% year-on-year, driven by strong Core EBITDA and reduced financing costs.
• Raising 2026 full-year net sales guidance to 19-21% growth at constant currency (previously 17-20%) based on a strong trajectory, and confirming Core EBITDA margin of approximately 26% at constant currency.